Drug Trial Radar · NCT02299505
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
306
Actual
Start
Apr 9, 2015
Primary completion
Jun 16, 2016
Study completion Mar 6, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I study to assess the systemic exposure, effiacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)
Conditions
- Non-Small Cell Lung Cancer
Interventions
ceritinibDrug
The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma concentration of ceritinibTime frame: Study Day 22
Locations
73 sites in 24 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
Loma Linda University
Loma Linda, California
Goshen Center for Cancer Care IU Health - SC
Indianapolis, Indiana
Maryland Oncology Hematology, P.A. SC-2
Rockville, Maryland
Essex Oncology of North Jersey PA SC
Belleville, New Jersey
Greenville Health System SC
Greenville, South Carolina
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
Salt Lake City, Utah
Novartis Investigative Site
Auckland, Australia
Novartis Investigative Site
Grafton, Auckland, Australia
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil
Novartis Investigative Site
Passo Fundo, Rio Grande do Sul, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Itajaí, Santa Catarina, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montería, Colombia
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Delhi, India
Novartis Investigative Site
Hyderabad, Andhra Pradesh, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Nashik, Maharashtra, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Novara, Italy
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Brescia, BS, Italy
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.